Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus lenalidomide versus rituximab plus chemotherapy in previously untreated follicular lymphoma
2011-002792-42Phase 3Completed
- Sponsor
- LYSARC
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Rituximab plus lenalidomide with Rituximab plus chemotherapy followed by rituximab (2 arms). Primary endpoints: Complete response rate at 120 weeks and Progression-free survival. Started May 2012; status: completed.
02
Drugs
lenalidomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2011-002792-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002792-42.